Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Botulinum neurotoxin injections for muscle-based (dystonia and spasticity) and non-muscle-based (neuropathic pain) pain disorders: a meta-analytic study

PRL. Siongco, RL. Rosales, AP. Moore, R. Freynhagen, K. Arimura, P. Kanovsky, R. Kaji, HH. Fernandez, D. Dressler

. 2020 ; 127 (6) : 935-951. [pub] 20200307

Jazyk angličtina Země Rakousko

Typ dokumentu časopisecké články, metaanalýza, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004885

Apart from the known efficacy of Botulinum Neurotoxin Type A (BoNT/A) in hyperactive striated and smooth muscles, different pain states have become potential targets of toxin effects. This present study determined the comparative toxin effectiveness in pain reduction among those patients injected with BoNT/A in muscle-based and in non-muscle-based conditions. Randomized controlled trials (RCTs) on the effect of BoNT/A on selected pain conditions were included. The conditions were spasticity and dystonia for muscle-based pain. For non-muscle-based pain, conditions included were painful diabetic neuropathy (PDN), post-herpetic neuralgia (PHN), trigeminal neuralgia (TN), complex regional pain syndrome (CRPS), and spinal cord injury (SCI). In view of possibly differing pathophysiology, myofascial pain, temporomandibular joint (TMJ), other joint or tendon pains, cervicogenic and lumbar pains, migraine and visceral pain syndromes were excluded. Standardized mean difference was used as the effect measure and computed with STATA. 25 RCTs were analyzed. Pooled estimates showed significantly lower pain score in the Treatment group (z = 5.23, p < 0.01, 95% CI = - 0.75, - 0.34). Subgroup analyses showed that BoNT/A significantly reduced both muscle-based (z = 3.78, p < 0.01, 95% CI = - 0.72, - 0.23) and non-muscle-based (z = 3.37, p = 0.001, 95% CI = - 1.00, - 0.27) pain. Meta-regression using four covariates namely dosage, route, frequency and duration was done which revealed that dosage significantly affects standardized mean differences, while the other three covariates were insignificant. The joint F-test was found to be insignificant (p value = 0.1182). The application of the model with these covariates does not significantly explain the derived heterogeneity of standardized mean differences. In conclusion, BoNT/A can be effectively used in muscle-based and non-muscle-based pain disorders. We detected no difference between the presence and magnitude of pain relief favoring muscle-based compared to non-muscle-based pain. Thus, we cannot say whether or not there might be independent mechanisms of toxin-induced pain relief for pain generated from either muscle or nerve hyperactivity.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004885
003      
CZ-PrNML
005      
20220127144846.0
007      
ta
008      
220113s2020 au f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00702-020-02163-5 $2 doi
035    __
$a (PubMed)32146504
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a au
100    1_
$a Siongco, Paula Ruth L $u Department of Neurology and Psychiatry, University of Santo Tomas Hospital, España, 1008, Manila, Philippines. paulasiongco@ymail.com
245    10
$a Botulinum neurotoxin injections for muscle-based (dystonia and spasticity) and non-muscle-based (neuropathic pain) pain disorders: a meta-analytic study / $c PRL. Siongco, RL. Rosales, AP. Moore, R. Freynhagen, K. Arimura, P. Kanovsky, R. Kaji, HH. Fernandez, D. Dressler
520    9_
$a Apart from the known efficacy of Botulinum Neurotoxin Type A (BoNT/A) in hyperactive striated and smooth muscles, different pain states have become potential targets of toxin effects. This present study determined the comparative toxin effectiveness in pain reduction among those patients injected with BoNT/A in muscle-based and in non-muscle-based conditions. Randomized controlled trials (RCTs) on the effect of BoNT/A on selected pain conditions were included. The conditions were spasticity and dystonia for muscle-based pain. For non-muscle-based pain, conditions included were painful diabetic neuropathy (PDN), post-herpetic neuralgia (PHN), trigeminal neuralgia (TN), complex regional pain syndrome (CRPS), and spinal cord injury (SCI). In view of possibly differing pathophysiology, myofascial pain, temporomandibular joint (TMJ), other joint or tendon pains, cervicogenic and lumbar pains, migraine and visceral pain syndromes were excluded. Standardized mean difference was used as the effect measure and computed with STATA. 25 RCTs were analyzed. Pooled estimates showed significantly lower pain score in the Treatment group (z = 5.23, p < 0.01, 95% CI = - 0.75, - 0.34). Subgroup analyses showed that BoNT/A significantly reduced both muscle-based (z = 3.78, p < 0.01, 95% CI = - 0.72, - 0.23) and non-muscle-based (z = 3.37, p = 0.001, 95% CI = - 1.00, - 0.27) pain. Meta-regression using four covariates namely dosage, route, frequency and duration was done which revealed that dosage significantly affects standardized mean differences, while the other three covariates were insignificant. The joint F-test was found to be insignificant (p value = 0.1182). The application of the model with these covariates does not significantly explain the derived heterogeneity of standardized mean differences. In conclusion, BoNT/A can be effectively used in muscle-based and non-muscle-based pain disorders. We detected no difference between the presence and magnitude of pain relief favoring muscle-based compared to non-muscle-based pain. Thus, we cannot say whether or not there might be independent mechanisms of toxin-induced pain relief for pain generated from either muscle or nerve hyperactivity.
650    12
$a botulotoxiny typu A $x terapeutické užití $7 D019274
650    12
$a dystonie $7 D004421
650    _2
$a lidé $7 D006801
650    _2
$a svaly $7 D009132
650    12
$a neuralgie $x farmakoterapie $7 D009437
650    12
$a nervosvalové látky $x terapeutické užití $7 D009465
650    _2
$a neurotoxiny $7 D009498
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rosales, Raymond L $u Department of Neurology and Psychiatry, University of Santo Tomas Hospital, España, 1008, Manila, Philippines $u Faculty of Medicine and Surgery, University of Santo Tomas, España, 1008, Manila, Philippines
700    1_
$a Moore, Austen Peter $u Department of Neurology, The Walton Centre NHS Foundation Trust, Lower Lamce, Fazakerley, Liverpool, L9 7LJ, UK
700    1_
$a Freynhagen, Rainer $u Zentrum für AnästhesiologieIntensivmedizinSchmerzmedizin and Palliativmedizin, Benedictus Krankenhaus Tutzing, Tutzing, Germany $u Klinik für Anästhesiologie, Technische Universität München, München, Germany
700    1_
$a Arimura, Kimiyoshi $u Clinical Neurophysiology, Department of Neurology and Geriatrics, Kagoshima University Hospital, Sakuragaoka, Kagoshima, Japan
700    1_
$a Kanovsky, Petr $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
700    1_
$a Kaji, Ryuji $u Department of Neurology, Tokushima University, Shinkuracho, Tokushima, Japan
700    1_
$a Fernandez, Hubert H $u Center for Neurological Restoration, Neurological Institute, Cleveland Clinic, Euclid Avenue, Cleveland, OH, USA
700    1_
$a Dressler, Dirk $u Movement Disorders Section, Department of Neurology, Hannover Medical School, Hannover, Germany
773    0_
$w MED00010058 $t Journal of neural transmission (Vienna, Austria : 1996) $x 1435-1463 $g Roč. 127, č. 6 (2020), s. 935-951
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32146504 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127144843 $b ABA008
999    __
$a ok $b bmc $g 1752178 $s 1156034
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 127 $c 6 $d 935-951 $e 20200307 $i 1435-1463 $m Journal of neural transmission $n J Neural Transm $x MED00010058
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace